Article By:
ChinaBio® Today
Sunday, June 26, 2022 12:39 PM EDT
InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a Series A financing of nearly $100 million.